Anti-Adalimumab (Humira®) Free Drug/ADA Dual ELISA Kit

(No reviews yet) Write a Review
SKU:
HUMB00012
€899

Description

ELISA Kit Technical Manual

Anti-Adalimumab (Humira®) Free Drug/ADA Dual ELISA Kit

Enzyme immunoassay for the semi-quantitative determination (screening) of total and free antibodies to adalimumab in serum and plasma. Free and Total Anti drug Antibody monitoring gained high importance along with measuring free drug from the patient samples. In order to make these measurements simple yet more informative. We have produced this ELISA Kit to measure Free and Total anti drug antibodies to Adalimumab simultaniously on the same plate. The kit is semi-quantitative and enables follow up of the patients to adjust the dose of the drug and/or frequency of administration.

Product Information

ApplicationFree drug
Required Volume (μl)10
Total Time (min)95
Sample TypeSerum, Plasma
Number of Assays96
Detection Limit (ng/mL)250 (ng/mL)
Spike Recovery (%)-
Shelf Life (year)1

About Anti-Adalimumab (Humira®) Free Drug/ADA Dual

Adalimumab (Humira®) is a tumor necrosis factor (TNF) blocker indicated for treatment of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Plaque Psoriasis. According to the manufacturer’s product insert, the use of Adalimumab (Humira®) was associated to the development of anti-adalimumab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Humira®. This might lead to severe complications. The Elisa Genie Antibody to Adalimumab ELISA Kit can be efficiently used for monitoring anti-adalimumab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-adalimumab antibodies. Demonstration of anti-adalimumab antibodies during treatment with adalimumab (Humira®) has a major concern and monitoring for the presence and/or quantitation of specific antibodies during clinical trials is an important issue for follow up of the treatment regimens. With the Elisa Genie Anti-Adalimumab (Humira®) Free Drug/ADA Dual ELISA Kit adalimumab-specific antibodies that are bound to adalimumab in serum and cannot be detected by free antibody detection kits can be determined in patients receiving Humira® and free antibody to adalimumab in patient serum and plasma. Elisa Genie ELISA test can be efficiently used for monitoring adalimumab-specific antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-adalimumab antibodies.

Anti-Adalimumab (Humira®) Free Drug/ADA Dual ELISA Kit test principle

The Elisa Genie Antibody to adalimumab (Humira®) ELISA is a sandwich assay for the determination of total antibodies against adalimumab in serum and plasma samples. During the first incubation period, the separation of adalimumab specific antibody-adalimumab immunocomplex is provided by adding dissociation buffer. After transferring dissociation mix to the plate, antibodies to adalimumab (ATA) separated from adalimumab in patient serum/ plasma samples are captured by the drug adalimumab (Humira®) coated on the wall of the microtiter wells and peroxidase-labelled specific conjugate. After washing away the unbound components from samples, the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogensubstrate. Finally, the reaction is terminated with an acidic stop solution. The intensity of the reaction colour is directly proportional to the concentration of ATA in sample. Elisa Genie S-ATAv4 Duo ELISA kit can be also used as a semi-quantitative (screening) test in free ADA determination without dissociation and neutralization steps. Peroxidase-labelled specific conjugate and diluted serum/plasma samples are transferred simultaneously to the adalimumab-coated plate and antibodies to adalimumab (ATA) in patient serum/ plasma samples are captured by the drug adalimumab (Humira®) coated on the wall of the microtiter wells and peroxidase-labelled specific conjugate. After washing away the unbound components from samples, the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The intensity of the reaction colour is directly proportional to the concentration of ATA in sample.

Trademarks

Humira® is a registered trademark of AbbVie Biotechnology, Inc.

View AllClose